|
PEIpro®-HQ
- 品牌：polyplus
- 产地：美国
- 货号：101000039
- 发布日期： 2022-09-20
- 更新日期： 2024-08-12
产品详请
| 产地 | 美国 |
| 品牌 | polyplus |
| 货号 | 101000039 |
| 用途 | 细胞转染 |
| 包装规格 | 1 L |
| 纯度 | 详询% |
| CAS编号 | |
| 是否进口 |
Reagent :PEIpro®-HQ.
Concentration :1 mg/mL.
Molecule delivered :Plasmid DNA and co-delivery of several plasmid DNA.
Applications :Large scale virus production for pre-clinical and early phase clinical trial.
Virus types :Mainly adenovirus, Adeno-Associated Viruses (AAV), Lentiviral Vector (LV), influenza virus, retrovirus, Virus-Like Particles (VLP).
Cell types :Mammalian producer cell lines (HEK-293, HEK-293 derivatives, BHK, VERO cell lines, virus-specific packaging cell lines) grown in adherent or suspension cultures.
Number of transfections :1 L of PEIpro®-HQ is sufficient to transfect on average 500 L of cell culture.
Storage :
Store PEIpro®-HQ at 5 °C ± 3°C.
Expiry date is indicated in the certificate of analysis (available in "My account") and on the product.
Provided with :
Certificate of Analysis.
Certificate of Origin.
Non-Hazardous Product Statement.
Regulatory documentation available upon request :
Batch Production Documentation.
Quality agreement.
Summary:PEIpro®-HQ is a Highly Qualified version of PEIpro® DNA transfection reagent manufactured in an ISO 9001 environment. Large-scale transfection protocols established with PEIpro® during process development are guaranteed to be seamlessly applicable with PEIpro®-HQ for manufacturing of viral vectors for pre-clinical and early phase clinical trial. To move on to therapeutic viral vector production for late phase clinical trials and in fine commercialization, PEIpro®-HQ should be replaced by PEIpro®-GMP, manufactured in compliance with EU “Guidelines of good manufacturing practice for medicinal products for human and veterinary use” (ICH Q7 and EudraLex Vol 4, Part II and Annex I).
Concentration :1 mg/mL.
Molecule delivered :Plasmid DNA and co-delivery of several plasmid DNA.
Applications :Large scale virus production for pre-clinical and early phase clinical trial.
Virus types :Mainly adenovirus, Adeno-Associated Viruses (AAV), Lentiviral Vector (LV), influenza virus, retrovirus, Virus-Like Particles (VLP).
Cell types :Mammalian producer cell lines (HEK-293, HEK-293 derivatives, BHK, VERO cell lines, virus-specific packaging cell lines) grown in adherent or suspension cultures.
Number of transfections :1 L of PEIpro®-HQ is sufficient to transfect on average 500 L of cell culture.
Storage :
Store PEIpro®-HQ at 5 °C ± 3°C.
Expiry date is indicated in the certificate of analysis (available in "My account") and on the product.
Provided with :
Certificate of Analysis.
Certificate of Origin.
Non-Hazardous Product Statement.
Regulatory documentation available upon request :
Batch Production Documentation.
Quality agreement.
Summary:PEIpro®-HQ is a Highly Qualified version of PEIpro® DNA transfection reagent manufactured in an ISO 9001 environment. Large-scale transfection protocols established with PEIpro® during process development are guaranteed to be seamlessly applicable with PEIpro®-HQ for manufacturing of viral vectors for pre-clinical and early phase clinical trial. To move on to therapeutic viral vector production for late phase clinical trials and in fine commercialization, PEIpro®-HQ should be replaced by PEIpro®-GMP, manufactured in compliance with EU “Guidelines of good manufacturing practice for medicinal products for human and veterinary use” (ICH Q7 and EudraLex Vol 4, Part II and Annex I).
